Scientific Programme (2024)
Thursday, 5 December 2024
Virtual
15:30 - 15:40 CET
Welcome and IntroductionOliver Schnell (Munich, Germany)
15:40 – 17:15 CET
Cardiovascular, kidney and metabolic care: Current and future perspectivesChair: Luc van Gaal (Antwerp, Belgium), Paola Fioretto (Padua, Italy)
15:40 – 15:55
Update on the treatment of heart failure - new approaches, new outcomesMikhail Kosiborod (Kansas City, USA)
15:55 – 16:10
Chronic kidney disease: Cornerstones of today´s treatment and opportunities for the futureBeatriz Fernández-Fernández (Madrid, Spain)
16:10 – 16:25
The next decade in the treatment of obesityBarbara McGowan (London, UK)
16:25 – 16:45
Organ Cross-Talk and Person-Centered Management of Obesity, CKD, Lipid Disorders, and DiabetesDirk Müller-Wieland (Aachen, Germany)
16:45 – 17:00
Microplastics and nanoplastics (MNPs): An emerging risk factor for cardiovascular diseaseAntonio Ceriello (Milan, Italy)
17:00 – 17:15
Discussion
17:15 – 17:30 CET
Break
17:30 – 18:45 CET
Updates from the Taskforce of the Guideline WorkshopChair: Helena Rodbard (Rockville, USA), Lars Rydén (Stockholm, Sweden)
17:30 – 17:45
The Taskforce of the Guideline Workshop: Aims and outcomesOliver Schnell (Munich, Germany)
17:45 – 18:00
Towards standardization of patient reported outcomes (PROs)Katharine Barnard-Kelly (Hampshire, UK)
18:00 – 18:15
Disparities in prevalence and treatment of diabetes, cardiovascular and chronic kidney diseasesJames R. Gavin (Atlanta, USA)
18:15 – 18:30
Network meta-analyses and clinical guidelines: what is missing for a precision medicine approach Francesco Giorgino (Bari, Italy)
18:30 – 18:45
Panel discussion
18:40 – 19:00 CET
Break
19:00 – 20:00 CET
Cardio-renal metabolic diseases: How can we connect the dots?Chair: Sarah Jarvis (London, UK)
Satellite Symposium kindly supported by Boehringer Ingelheim
19:00 – 19:03
Welcome and introduction Sarah Jarvis (London, UK)
19:03 – 19:13
Why does connecting the dots matter in CRM diseases?Nikolaus Marx (Aachen, Germany)
19:13 – 19:23
Connecting the dots in CRM disease: how do we work together?Sarah Jarvis (London, UK)
19:23 – 19:33
Connecting the dots in understanding CRM disease: does aldosterone have a role?Per-Henrik Groop (Helsinki, Finland)
19:33 - 19:58
Panel discussion: Connecting the dots in multidisciplinary care
19:58 - 20:00
Closing remarks/final thoughtsSarah Jarvis (London, UK)
20:00 – 20:45 CET
Oral Presentations – Part 1Chair: Mahmoud Ibrahim (Charlotte, USA)
OP 1: Micro- and Macroangiopathy Related to Diabetes: Beyond HbA1c, Should We Rely on New Glucose Metrics?Bruno Guerci (Nancy, France)
OP 2: The Impairment of Myocardial Structure in Patients with Type 2 Diabetes Mellitus without Cardiovascular DiseaseIvanna Zubovych (Kyiv, Ukraine)
OP 3: Characterizing the Healthcare Resource Use and Costs for Patients Aged 65-89 Years with Laboratory Evidence of CKD With and Without a Recorded DiagnosisJieling Chen (Gaithersburg, USA)
OP 4: Improvement of Health-Related Quality of Life after Bariatric Surgery in Patients with Severe Obesity and Type 2 DiabetesTamar Shervashidze (Tbilisi, Georgia)
20:45 CET
Closing of Day 1
Friday, 6 December 2024
Virtual
08:30 – 09:30 CET
Type 1 Diabetes – Early detection and preventive treatment approachesChairs: Chantal Mathieu (Leuven, Belgium), Othmar Moser (Bayreuth, Germany)
08:30 – 08:45
Early detection of Type 1 Diabetes - risk evaluation, markers and early diagnosis programsThomas Danne (Lissabon, Portugal)
08:45 – 09:00
Treatment strategies for delaying the onset of Type 1 DiabetesColin M. Dayan (Cardiff, UK)
09:00 – 09:15
Future directions in the treatment of CKD in Type 1 Diabetes Hiddo Heerspink (Groningen, Netherlands)
09:15 – 09:30
Discussion
09:30 – 10:45 CET
Advancing diabetes management through technological innovationsChairs: Tadej Battelino (Ljubljana, Slovenia), Doina Catrinoiu (Constanta, Romania)
09:30 – 09:45
Continuous glucose monitoring in Type 2 DiabetesStefano del Prato (Pisa, Italy)
09:45 – 10:00
CGM and cardiovascular perspectivesUlf Landmesser (Berlin, Germany)
10:00 – 10:15
CGM, hypoglycemia and risk predictionLutz Heinemann (San Diego, USA)
10:15 – 10:30
Automated Insulin delivery (AID), physical activity and exercise in Type 1 DiabetesOthmar Moser (Bayreuth, Germany)
10:30 – 10:45
Discussion
10:45 – 11:00 CET
Break
11:00 – 12:00 CET
CKD and heart failure: current perspectives on diagnosis and treatmentChair: Per-Henrik Groop (Helsinki, Finland)
11:00 – 11:15
UACR and eGFR: barriers of implementationElke Schaeffner (Berlin, Germany)
11:15 – 11:30
KDIGO guidelines 2024: consistence with ESC?Michel Jadoul (Brussels, Belgium)
11:30 – 11:45
REVOLUTIONizing heart failure diagnosisLisa Anderson (London, UK)
11:45 - 12:00
Discussion
12:00 – 12:30 CET
Diabetes and the heart: exploring effects beyond heart failureChair: Nikolaos Papanas (Alexandroupolis, Greece), Boris Mankovsky (Kyiv, Ukraine)
12:00 – 12:10
Cardiac autonomic neuropathy: current experimental and clinical practice considerationsAlin Stirban (Birkenwerder, Germany)
12:10 – 12:20
Mitochondrial metabolomics and the diabetic heartEberhard Standl (Munich, Germany)
12:20 – 12:30
Discussion
12:30 – 13:30 CET
Primary care at the forefront of cardiorenal and metabolic disease managementChair: Dipesh Patel (London, UK), Pinar Topsever (Istanbul, Turkey)
12:30 – 12:45
Cardiovascular Risk evaluation in primary careNaresh Kanumilli (Manchester, UK)
12:45 – 13:00
Interconnectedness of Heart, Kidney and Metabolism – Perspectives of PCPsXavier Cos (Barcelona, Spain)
13:00 - 13:15
Empowering diabetes self-management: the path to successTatjana Milenkovic (Skopje, Macedonia)
13:15 - 13:30
Discussion
13:30 - 14:00 CET
Break
14:00 – 14:45 CET
Targeting obesity – combating metabolic diseasesChairs: Luca Busetto (Padua, Italy), Matthias Blueher (Leipzig, Germany)
14:00 – 14:15
Obesity as a therapeutic target in heart failure therapyLuc van Gaal L (Antwerpen, Belgium)
14:15 – 14:30
GIP/GLP-1 receptor agonists – a new dawn in sleep apnea therapy?Igor Harsch (Saalfeld, Germany)
14:30 – 14:45
Discussion
14:45 - 15:30 CET
Eating for Health: Nutritional Strategies in Metabolic and Cardiovascular CareChair: Linong Ji (Beijing, China), Dario Rahelić (Zagreb, Croatia)
14:45 - 15:00
On the Path to Precision Nutrition in Cardiometabolic DiseasesAndreas Pfeiffer (Potsdam, Germany)
15:00 - 15:15
Navigating Nutrition under Incretin-Based TherapiesJaime Almandoz (Texas, USA)
15:15 - 15:30
Discussion
15:30 - 16:15 CET
Liver in the Spotlight: Current Practices and New HorizonsChair: Frank Tacke (Berlin, Germany), Linong Ji (Beijing, China)
15:30 - 15:45
Diagnosis and Treatment of MASLD: Current State of the ArtWendy Spearman (Cape Town, South Africa)
15:45 - 16:00
The liver – a new target for incretin therapies?Frank Tacke (Berlin, Germany)
16:00 - 16:15
Discussion
16:15 - 16:30 CET
Break
16:30 - 17:30 CET
Industry´s perspective - Panel Discussion
17:30 – 18:15 CET
Oral Presentations – Part 2Chair: Thomas Forst (Mainz, Germany)
OP 5: Aldosterone Synthase Inhibitor Vicadrostat (BI 690517) ± Empagliflozin in a CKD Phase II Trial: Effects on Albuminuria and SBP in Patients with/without T2DPeter Rossing (Copenhagen, Denmark)
OP 6: Endothelial Dysfunction and Cardiovascular Pathology in Patients with Metabolic Dysfunction-Associated
Steatotic Liver DiseaseKateryna Pivtorak (Vinnytsia, Ukraine)
Steatotic Liver DiseaseKateryna Pivtorak (Vinnytsia, Ukraine)
OP 7: Consistency in Glucose Monitoring, Consistency in Care: Standardizing CGM Evaluation for Better Patient OutcomesGuido Freckmann (Ulm, Germany)
OP 8: Age is No Barrier to Diabetes Technology: Improvements in Glycemia in Older People with Type 2 Diabetes Mirror Engagement Levels with the OneTouch Reveal® Mobile Diabetes Management AppElizabeth Holt (Malvern, PA, USA)
18:15 – 18:30 CET
Abstract Awards and ClosingOliver Schnell (Munich, Germany)